0001433714-20-000009.txt : 20200225 0001433714-20-000009.hdr.sgml : 20200225 20200225162607 ACCESSION NUMBER: 0001433714-20-000009 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200225 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200225 DATE AS OF CHANGE: 20200225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CASTLIGHT HEALTH, INC. CENTRAL INDEX KEY: 0001433714 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 261989091 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36330 FILM NUMBER: 20651023 BUSINESS ADDRESS: STREET 1: 150 SPEAR STREET STREET 2: SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94105 BUSINESS PHONE: 415-671-4683 MAIL ADDRESS: STREET 1: 150 SPEAR STREET STREET 2: SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94105 FORMER COMPANY: FORMER CONFORMED NAME: VENTANA HEALTH SERVICES, INC. DATE OF NAME CHANGE: 20090831 FORMER COMPANY: FORMER CONFORMED NAME: MARIA HEALTH INC DATE OF NAME CHANGE: 20080429 8-K 1 cslt-20200225.htm 8-K cslt-20200225
false000143371400014337142020-02-252020-02-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
February 25, 2020
Date of Report (Date of earliest event reported)
CASTLIGHT HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3633026-1989091

(State or other jurisdiction of incorporation)

(Commission File Number)
(I.R.S. Employer Identification Number)
150 Spear Street, Suite 400
San Francisco, CA 94105
(Address of principal executive offices)
(415) 829-1400
(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)
Not applicable

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class B Common Stock, par value $0.0001 per shareCSLTNew York Stock Exchange


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 2.02 Results of Operations and Financial Condition.

On February 25, 2020, Castlight Health, Inc. ("the Company") issued a press release announcing its results for the three and 12 months ended December 31, 2019. The press release is attached to this current report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document filed by the Company with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form 8-K generally), except as shall be expressly set forth by specific reference in such filing.

The Company is making reference to financial measures not presented in accordance with generally accepted accounting principles in the United States (“GAAP”) in the press release. A reconciliation of these non-GAAP financial measures to the nearest comparable GAAP financial measures is contained in the attached Exhibit 99.1 press release.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

ExhibitDescription




SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CASTLIGHT HEALTH, INC.
Date:February 25, 2020By:/s/ Will Bondurant
Will Bondurant
Chief Financial Officer




EX-99.1 2 exh991-pressreleaseq41.htm EX-99.1 Document

image11.jpg
Castlight Health Announces Fourth Quarter and Full Year 2019 Results

Company Provides Initial 2020 Financial Outlook

SAN FRANCISCO - February 25, 2020 - Castlight Health, Inc. (NYSE:CSLT), a leading health benefits platform provider, today announced results for its fourth quarter and full year ended December 31, 2019.

“In the fourth quarter, we continued our momentum with execution against our top priorities, including: the launch of the Castlight Care Guides high-touch pilot, the hire of our chief commercial officer, industry veteran Keith Reynolds, and the pipeline development and advancement by our new dedicated health plan team”, said Maeve O’Meara, chief executive officer at Castlight Health. “The work we’ve done over the last two quarters provides a solid foundation for the Company to execute on our two-prong strategy of revitalizing our employer business while unlocking new growth vectors, starting with health plans.”

Financial performance for the three months ended December 31, 2019 compared to the three months ended December 31, 2018 includes:
GAAP total revenue of $36.4 million, compared to $42.1 million
GAAP gross margin of 55.3%, compared to 65.0%
Non-GAAP gross margin of 57.8%, compared to 68.0%
GAAP operating loss of $12.2 million, compared to $3.8 million
Non-GAAP operating loss of $8.1 million, compared to income of $1.6 million
GAAP net loss per basic and diluted share of $0.08, compared to a net loss per basic and diluted share of $0.03



Non-GAAP net loss per basic and diluted share of $0.05, compared to a net income per basic and diluted share of $0.01
Cash provided by operations of $4.0 million, compared to $7.5 million

Financial performance for the 12 months ended December 31, 2019 compared to the 12 months ended December 31, 2018 includes:

GAAP total revenue of $143.3 million, compared to $156.4 million
GAAP gross margin of 58.8%, compared to 61.5%
Non-GAAP gross margin of 61.6% compared to 65.3%
GAAP operating loss of $41.3 million, compared to a loss of $39.9 million
Non-GAAP operating loss of $21.7 million, compared to a loss of $12.7 million
GAAP net loss per basic and diluted share of $0.28, compared to a net loss per basic and diluted share of $0.29
Non-GAAP net loss per basic and diluted share of $0.14, compared to a net loss per basic and diluted share of $0.09
Cash used in operations of $17.4 million, compared to $18.6 million used in operations

Total cash, cash equivalents and marketable securities was $59.4 million as of December 31, 2019.

A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

Business Outlook
For the full year 2020, the Company expects:



GAAP revenue between $130 million and $135 million
Non-GAAP operating loss between $17 million and $22 million
Non-GAAP net loss per share between $0.12 and $0.15, based on approximately 150 million to 151 million shares


Quarterly Conference Call
Castlight Health senior management will host a conference call to discuss its fourth quarter and full year 2019 results and business outlook today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the Company’s Investor Relations website at http://ir.castlighthealth.com. An archive of the webcast can also be accessed through the same link. The live conference call can be accessed by dialing (833) 238-7953 and the replay will be available for one week at (800) 585-8367. The conference ID number for the live call and replay is 2757629.


About Castlight Health
Castlight is on a mission to make it as easy as humanly possible for its users to navigate the healthcare system and live happier, healthier, more productive lives. Our health navigation platform connects hundreds of health vendors, benefits resources, and plan designs into one comprehensive health and wellbeing experience. We guide individuals—based on their unique profile—to the best resources available to them, whether they are healthy, chronically ill, or actively seeking medical care. Castlight transforms the employee benefit experience into a deeply personalized, yet simple, guided one, empowering better-informed patient decisions to unlock better healthcare outcomes and maximizing return on healthcare investments.




For more information visit www.castlighthealth.com. Follow us on Twitter and LinkedIn and Like us on Facebook.

Non-GAAP Financial Measures
To supplement Castlight Health’s financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating income (loss), non-GAAP net income (loss) and non-GAAP net income (loss) per share. Non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating income (loss), and non-GAAP net income (loss) exclude stock-based compensation, certain legal expenses, amortization of intangibles, restructuring charges, capitalization and amortization of internal-use software, and lease exit and related charges.

We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company’s core operating results and comparison of operating results across reporting periods, and can help enhance overall understanding of the company’s historical financial performance.

We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP operating loss and net loss per share guidance for the full year 2020 to comparable GAAP measures because we do not provide guidance for stock-based compensation expense, and capitalization and amortization of internal-use software, which are reconciling items between GAAP and non-GAAP. The factors that may impact our future stock-based compensation expense, and capitalization and amortization of internal-use software are out of our control and/



or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort. Factors include our market capitalization and related volatility of our stock price and our inability to project the cost or scope of internally produced software.

These non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP.

Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the company’s financial information in its entirety and not rely on a single financial measure.

Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements about Castlight Health’s expectations, plans, intentions, and strategies, including, but not limited to, statements regarding Castlight Health’s 2020 full year projections, executive leadership, the success of our strategy and our expectations for our future business and financial performance. Statements including words such as “anticipate,” “believe,” “estimate,” “will,” “continue,” “expect,” or “future,” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health’s Annual Report on Form 10-K and other documents filed with or furnished to the Securities and Exchange Commission. All forward-looking statements in this press release are



based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements.

Copyright 2020 Castlight Health, Inc. Castlight Health® is the registered trademark of Castlight Health, Inc. Other company and product names may be trademarks of the respective companies with which they are associated.






CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(unaudited)
 
As of
December 31, 2019December 31, 2018
Assets
Current assets:
Cash and cash equivalents$43,017  $66,005  
Marketable securities16,411  11,327  
Accounts receivable and other, net31,397  26,816  
Prepaid expenses and other current assets4,645  3,680  
Total current assets95,470  107,828  
Property and equipment, net4,856  3,963  
Restricted cash, non-current1,144  1,325  
Deferred commissions14,718  20,142  
Deferred professional service costs6,711  10,133  
Intangible assets, net12,178  16,209  
Goodwill91,785  91,785  
Operating lease right-of-use assets, net13,906  —  
Other assets2,016  2,129  
Total assets$242,784  $253,514  
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$19,596  $9,556  
Accrued expenses and other current liabilities10,454  15,454  
Accrued compensation8,770  5,975  
Deferred revenue10,173  20,193  
Operating lease liabilities5,914  —  
Total current liabilities54,907  51,178  
Deferred revenue, non-current572  1,030  
Debt, non-current1,395  3,254  
Operating lease liabilities, non-current11,823  —  
Other liabilities, non-current1,213  3,381  
Total liabilities69,910  58,843  
Stockholders’ equity 172,874  194,671  
Total liabilities and stockholders’ equity $242,784  $253,514  





CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(unaudited)
 
 Three Months Ended December 31,Year Ended December 31,
2019201820192018
Revenue:
Subscription$34,723  $39,408  $137,393  $143,901  
Professional services and other1,724  2,692  5,915  12,503  
Total revenue, net36,447  42,100  143,308  156,404  
Cost of revenue:
Cost of subscription(1)
9,150  7,819  34,067  34,691  
Cost of professional services and other(1)
7,150  6,902  25,007  25,498  
Total cost of revenue16,300  14,721  59,074  60,189  
Gross profit 20,147  27,379  84,234  96,215  
Operating expenses:
Sales and marketing(1)
10,664  10,419  38,597  49,134  
Research and development(1)
14,487  14,531  58,994  61,355  
General and administrative(1)
7,238  6,220  27,981  25,620  
Total operating expenses32,389  31,170  125,572  136,109  
Operating loss(12,242) (3,791) (41,338) (39,894) 
Other income, net496  (248) 1,336  188  
Net loss$(11,746) $(4,039) $(40,002) $(39,706) 
Net loss per share, basic and diluted$(0.08) $(0.03) $(0.28) $(0.29) 
Weighted-average shares used to compute basic and diluted net loss per share
147,359  140,508  145,172  137,686  

(1)Includes stock-based compensation expense as follows:
 Three Months Ended December 31,Year Ended December 31,
 2019201820192018
Cost of revenue:
Cost of subscription$179  $222  $774  $1,017  
Cost of professional services and other216  239  953  1,177  
Sales and marketing175  615  2,142  3,770  
Research and development1,369  1,854  6,100  7,214  
General and administrative1,217  1,193  5,034  4,954  





CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
 Three Months Ended December 31,Year Ended December 31,
 2019201820192018
Operating activities:
Net loss$(11,746) $(4,039) $(40,002) $(39,706) 
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization1,552  1,587  5,920  6,858  
Stock-based compensation3,156  4,123  15,003  18,132  
Amortization of deferred commissions3,365  4,088  10,768  13,105  
Amortization of deferred professional service costs2,132  1,917  5,242  5,268  
Non-cash operating lease expense1,396  —  5,315  —  
Lease exit and related charges—  564  —  2,634  
Accretion and amortization of marketable securities (124) (238) (516) 
Changes in operating assets and liabilities:
Accounts receivable and other, net4,045  3,419  (4,581) (4,883) 
Deferred commissions(841) (555) (5,344) (5,735) 
Deferred professional service costs(385) (625) (1,686) (2,735) 
Prepaid expenses and other assets924  1,297  102  178  
Accounts payable6,900  3,999  9,278  5,744  
Operating lease liabilities(1,459) —  (5,726) —  
Accrued expenses and other liabilities(688) (1,355) (3,760) 290  
Deferred revenue(7,588) (6,904) (10,478) (9,219) 
Accrued compensation3,223  114  2,795  (7,966) 
Net cash provided by (used in) operating activities3,992  7,506  (17,392) (18,551) 
Investing activities:
Purchase of property and equipment(1,241) (119) (1,953) (2,014) 
Purchase of marketable securities(7,520) (6,544) (30,589) (31,974) 
Maturities of marketable securities11,075  16,860  25,745  53,210  
Net cash provided by (used in) investing activities2,314  10,197  (6,797) 19,222  
Financing activities:
Proceeds from exercise of stock options1,136  1,867  3,060  4,480  
Principal payments on long-term debt(465) (465) (1,859) (465) 
Net cash provided by financing activities671  1,402  1,201  4,015  
Net increase (decrease) in cash, cash equivalents and restricted cash
6,977  19,105  (22,988) 4,686  
Cash, cash equivalents and restricted cash at beginning of period
37,365  48,225  67,330  62,644  
Cash, cash equivalents and restricted cash at end of period$44,342  $67,330  $44,342  $67,330  
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents$43,017  $66,005  $43,017  $66,005  
Restricted cash included in Prepaid and other current assets181  —  181  —  
Restricted cash, non-current1,144  1,325  1,144  1,325  
Total cash, cash equivalents and restricted cash$44,342  $67,330  $44,342  $67,330  






CASTLIGHT HEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
(unaudited)

Three Months EndedYear Ended
December 31, 2019September 30, 2019December 31, 2018December 31, 2019December 31, 2018
Gross profit:
GAAP gross profit subscription$25,573  $26,383  $31,589  $103,326  $109,210  
Stock-based compensation179  180  222  774  1,017  
Amortization of internal-use software—  —  120  —  778  
Amortization of intangibles530  660  678  2,364  2,712  
Reduction in workforce—  —  —  —  130  
Non-GAAP gross profit subscription$26,282  $27,223  $32,609  $106,464  $113,847  
GAAP gross margin subscription73.6 %75.6 %80.2 %75.2 %75.9 %
Non-GAAP gross margin subscription75.7 %78.0 %82.7 %77.5 %79.1 %
GAAP gross loss professional services$(5,426) $(5,423) $(4,210) $(19,092) $(12,995) 
Stock-based compensation216  236  239  953  1,177  
Reduction in workforce—  —  —  —  173  
Non-GAAP gross loss professional services$(5,210) $(5,187) $(3,971) $(18,139) $(11,645) 
GAAP gross margin professional services(315)%(967)%(156.4)%(323)%(103.9)%
Non-GAAP gross margin professional services(302)%(925)%(147.5)%(307)%(93.1)%
GAAP gross profit $20,147  $20,960  $27,379  $84,234  $96,215  
Impact of non-GAAP adjustments925  1,076  1,259  4,091  5,987  
Non-GAAP gross profit $21,072  $22,036  $28,638  $88,325  $102,202  
GAAP gross margin 55.3 %59.1 %65.0 %58.8 %61.5 %
Non-GAAP gross margin 57.8 %62.1 %68.0 %61.6 %65.3 %
Operating expense:
GAAP sales and marketing$10,664  $9,829  $10,419  $38,597  $49,134  
Stock-based compensation(175) (678) (615) (2,142) (3,770) 
Amortization of intangibles(529) (528) (273) (1,601) (1,265) 
Reduction in workforce—  —  —  —  (1,055) 
Non-GAAP sales and marketing$9,960  $8,623  $9,531  $34,854  $43,044  
GAAP research and development$14,487  $14,295  $14,531  $58,994  $61,355  
Stock-based compensation(1,369) (1,294) (1,854) (6,100) (7,214) 
Reduction in workforce—  —  —  —  (522) 
Certain legal expenses—  —  —  (191) —  
Capitalization of internally developed software80  —  —  80  —  
Lease exit and related charges—  —  (167) —  (2,178) 
Non-GAAP research and development$13,198  $13,001  $12,510  $52,783  $51,441  
GAAP general and administrative$7,238  $6,440  $6,220  $27,981  $25,620  
Stock-based compensation(1,217) (625) (1,193) (5,034) (4,954) 
Amortization of intangibles(16) (16) (17) (66) (67) 
Certain legal expenses—  —  —  (533) —  
Reduction in workforce—  —  —  —  (172) 
Non-GAAP general and administrative$6,005  $5,799  $5,010  $22,348  $20,427  
GAAP operating expense$32,389  $30,564  $31,170  $125,572  $136,109  
Impact of non-GAAP adjustments(3,226) (3,141) (4,119) (15,587) (21,197) 
Non-GAAP operating expense$29,163  $27,423  $27,051  $109,985  $114,912  


CASTLIGHT HEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
(unaudited)

Operating loss:
GAAP operating loss$(12,242) $(9,604) $(3,791) $(41,338) $(39,894) 
Impact of non-GAAP adjustments4,151  4,217  5,378  19,678  27,184  
Non-GAAP operating loss (income)$(8,091) $(5,387) $1,587  $(21,660) $(12,710) 
Net (loss) income and net (loss) income per share:
GAAP net loss$(11,746) $(9,336) $(4,039) $(40,002) $(39,706) 
Total pre-tax impact of non-GAAP adjustments4,151  4,217  5,378  19,678  27,184  
Non-GAAP net (loss) income$(7,595) $(5,119) $1,339  $(20,324) $(12,522) 
GAAP net loss per share, basic and diluted$(0.08) $(0.06) $(0.03) $(0.28) $(0.29) 
Non-GAAP net (loss) income per share, basic and diluted$(0.05) $(0.04) $0.01  $(0.14) $(0.09) 
Shares used in basic and diluted net (loss) income per share computation147,359  145,701  140,508  145,172  137,686  





Castlight Media Contact:
Courtney Lamie
press@castlighthealth.com
276-492-4248



Castlight Investor Contact:
ir@castlighthealth.com
415-829-1680






EX-101.SCH 3 cslt-20200225.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 cslt-20200225_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 cslt-20200225_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 cslt-20200225_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two City Area Code City Area Code Cover page. Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 cslt-20200225_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 image11.jpg begin 644 image11.jpg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end JSON 10 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cslt-20200225.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "cslt-20200225_cal.xml" ] }, "definitionLink": { "local": [ "cslt-20200225_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "cslt-20200225.htm" ] }, "labelLink": { "local": [ "cslt-20200225_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cslt-20200225_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "cslt-20200225.xsd" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cslt", "nsuri": "http://www.castlighthealth.com/20200225", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cslt-20200225.htm", "contextRef": "i7bacbb77705041f5ae79badc06e7cc1a_D20200225-20200225", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.castlighthealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cslt-20200225.htm", "contextRef": "i7bacbb77705041f5ae79badc06e7cc1a_D20200225-20200225", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 cslt-20200225_htm.xml IDEA: XBRL DOCUMENT 0001433714 2020-02-25 2020-02-25 false 0001433714 8-K 2020-02-25 CASTLIGHT HEALTH, INC. DE 001-36330 26-1989091 150 Spear Street Suite 400 San Francisco CA 94105 415 829-1400 Class B Common Stock, par value $0.0001 per share CSLT NYSE false false false false false XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.castlighthealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports cslt-20200225.htm cslt-20200225.xsd cslt-20200225_cal.xml cslt-20200225_def.xml cslt-20200225_lab.xml cslt-20200225_pre.xml exh991-pressreleaseq41.htm http://xbrl.sec.gov/dei/2019-01-31 true true EXCEL 15 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 16 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover
Feb. 25, 2020
Cover page.  
Document Type 8-K
Document Period End Date Feb. 25, 2020
Entity Registrant Name CASTLIGHT HEALTH, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36330
Entity Tax Identification Number 26-1989091
Entity Address, Address Line One 150 Spear Street
Entity Address, Address Line Two Suite 400
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94105
City Area Code 415
Local Phone Number 829-1400
Title of 12(b) Security Class B Common Stock, par value $0.0001 per share
Trading Symbol CSLT
Security Exchange Name NYSE
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001433714
ZIP 17 0001433714-20-000009-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001433714-20-000009-xbrl.zip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ω@'E3D#9T9 M@Y79[9]7'XZ# MTH&-$N4^S6ZOTRS 4BSBI(B3 LP ,\ ,, /, +, P8P \P= ;/6_NEWL@#Y M%5>V]5,O<.DF)S_L>A5=U.C#>9H<[J[&X'8J3;X4K0""W&HAAO6"@J\+2J2I M1[>)[K8>2%U59H*@2\S5 E !J.!-5. 076^@RB&H %0@QF"!"E84E*$36VV] M/ RH %0 *F@[-J7:Q&P_:PA< "X %[3-!9I!7+/U@ACR75Q"@4.O^&%=:N*( % M!8 "[+$"N&JO@34@*,"^*X )X%Q95MSYW(1= OBS2X/>S[ M.>6B&HYHDOOB[+B38B%2UUK?420DM%";5#8@&P R@-P)(+>^S0% !I#?/F"> MU4"1/@ 90-YY.1FB.0WD37<3RH)EC(CLON[V#*\.9M$V=KA&-R-+ H2$ 6: M&6 &F %F@!E@!I@!YIT[LT[K1R?( F2 M5^?>N"R5!-6Y#ZRMY]XV(RY!@"7F>@%8 "SP1A;07 =D-Z>X9^Y#%MDL?4ACO?P3V/!X:ZW2I;'=CMB+,D)<*OI[<9 M2 9^@=\WFD^FTP."@6!Y$6RH;:;W ;_ [QLM"*/79F::! !^T_%6547L]6 MH;Q07BBO?,KK$,-!]6LH+Y17/N5U3:(;)I07R@OEE4YY/9OHF@7EE7*3G<@U MSL^&(S\HE/1:229Y>G[XSW%>#&E2"+*_3HKE2$]O0#V[6;=Q;]/&I0"R1E2G M@:.Z &5 >?=0UJT&PA6 ,J"\ZP$SB>II@#*@+#^4+>*Y#2S?=A/*R"#99)-9 MVUDD"^L4J:B!M9&L1.(OG7M(>MNQN#7$)@C&]CS*#D[H,B?H1&W_@'-P C@! MG" ,)[C$-EQP C@!G- ^N,7@!- $< (X04Y.T%2=Z"H""J*&2_>B MO+88F3X=J*MG6;W6#W"5OK3>WB[@=4$!O%[K"]50 "A :R-I6[T&-CA" : MDBB Y?8:"'M" : DBB K?5:WPP@O0(@\VF3S*>&W?G-]HL)K:R6T\1LU8&- M=2B&*0^(;;T)IQL@!HAW"6*W"<<9( :(=VO[MYX'"! #Q&\-83:PB-4Y$*.^ M-MJ"MJ M: OJ:[\]1N@T-FM=C&CF%ZQ9"OTYHDE.?_O%(G(5_MN:698.+9= MAO(F /%B$-N."Q #Q)*#6 ,3 \22@U@GFJD#QH"QW# VB..H@+%L%;Y$=E9/ MABGKP+]+!Y6?\!C]H. Y*9S5*E/LT MN[U.LX!B:74-^+FZIA]CYSXBH@ SP PP \P ,\ ,, /, /-B1U:UD 8CW<*K MJ$[LM!ZS2+OT]_O\N(T+IR^6E4@,YA'/%NG D=>D)@C$Q PY@Q) "5LX9I;8 MNDBGT($20 F@A):M!,L0Z5P^4 (H 930;HD#D[A6Z[NDP0G@!'""*)Q@&D0U MP0D[")@NKYB]VSJO6VS+FXYOW&E+16H+I :I;;4M*[+KQF)KFV_;;\"$ZE^U M F6&T2Z4#PN+*P&N7%3,:$[]+!B4ZXHAO:-Q.AK2I$#];S'L?1%->LTDIHM* MAO#DH;Q2*J_NM7Z8/)07R@OEW41Y!5AT@_)">:&\:XO#:&\ M&YS"3@P+9G.+J?T=W:.. N#;V'%CV-LMJ=;-'3?8."8XC'7/!(P!8]EA[%J M,6 L.8QMHJFHGPP82PYCA^@:V+@=E[6C9V>RA;-T'\BAL;1ODH]A^.DC2AK^SLP*4[O!0+ MYBN#_I2UWX\2):8W?JS0GWS%O+GSQSH8$D2U5<2W 6: &6 &F %F@+FQ/!!O MNZ>2 <0 ,1A9:#!C$7UU-]8?105K^Y/3M&F6^''\,"G$0!G&TNOBWL^PNKZZ M9-W6:Y<+"3A$O"7#,99O &: &6 &F$4#,RP,X+@+. 8IM^[==G21]COU6UOI*-#@!G !.$(43+)TXK@%. "> $]H' MMR"@+("L=O/1&'0W2C]24Q(95JSSU7Z*[PNFLS][/U,#5T M%[H+W=U =W4=N@O=A>[*I[NZ0SRW];@OE!?*"^5=7WDM8F/FQ@%CR6%L$L\"C-_L ML(IY2!4N%2S11^0XP\DP91UX4MW<3VZB?MQ<^;<.5F@\T&P<>BA#[!X8!H:! MX0YC>+OQ7F 8&-Y]O!<\# S+CF'P,*(+';T460PK@QZ'@*/PJXA6 98= &: M&6 &F %F@)GG-1A(S@&(Y08Q&+GU9/R.+I+_H.$X*%?(F2][GV:WUVD6X*QO M 52SFX%!!+:HV,17;8]Y:*ZL--#TG93V''3 M I]/:TZ_E*T DMQJ!8SU0DNO"THD K.)JEIM1^-6%9D@X!(SZ-P^$X ,.G# M 7$\3U@^ "6 $D ).Z<$M8FCT4 )H 10@IR4H.O$,!NH(0]. "> $R3E!)68 MN@-.:#YP:Y<577I58M@GEA?)">>537HUH M3NN+2U!>*"^4=VUQ:+I%+$>']D)[H;WR::]A$TV%U]MB"GM'=V*?#4=^4/!" MYAAKI@88 \9RP]@DFN8!QH"Q MW##6F-?NHO0S<"PYCG5^7"5PW([KVL&\D>GN:W%R1Y PW>6$:8]HMM%V_*T3 M"=/[%%H')W29$QQBZN $< (X00!P"\,)JJ6!$\ )X(3VP2T&)VBJ1SQ7W,)- M( 60 DAAUZ2@F<336L_'ZP0I8 LV-GA":I :I :IS;2TG!8^%#Z[G?T;1G>? M/K(?T\DUS2-^ LU11N.R6N_Q?106@R--909"W1W3JAXW[S:_SR;+<4&/Z]E8 MG;V_NJ>:+#]][/-VU/-5^?'LST'V.-W?T,-^1OW;0_^ZH-F1']_[#_G3]]+C0&'W1Q'"3VG)Y=7W ML]^_72G?OIQ\O_I&E+/ST]Y324G7J1]?3B_.3\^^GYU_SP5FB%(-TS)X1YD2A/P/*%'=$ M&;('?D:5T"_\][+W<9SXXS J:/BR)Z_H^=*^#OWL)DHF)KU=\4W)69-[ZBM* MPO/'13JYI2*\\I.:,ID$8G^4TZ/)+R\8M_P[2D+V[B.5O6MR''>4E%TNW_M( M*SVUII;:MJX;5'_?J[Y[YK-47QIZSS:]Q=\OO7GYEVI/=S>]6>UIR[ZTC$WO M7=YDK6>HIEQ-EE#*DC;96?'F3B4&.8V%!RZF^4!QFN>__6*YP@40\7Z\'^_? MT_<+MC51U/S.9[F=G,N;S1W>Y_W1;\FD%F,UY4#3B6[B="\I]DE <46 J""* MZQ%;-:&WT%OHK51Z:Q#'PS9QZ"WT5BZ]-35B&"X4%XH+Q95*<0V/N!XL9>EV M4*/XUW9JS@E=W\ D6ON[?H2$F)@Y_(#R$BCK6NLG@P'*@/(V#L,UG-8/O@24 M >4M;!?RB TL \M=P++N$,W%(3 MNK,=3!B94Q",)XTH!U$2I$/:<-QDDUV\ MB+JM*RB12.S )6JK"V"KBDL08.UYA!TLT$T68"YFJ^5YP0)@ ;! V\XYK]&] M?7\&3 F$&.PP 2KV@.Z1FQ;A4$ &@ -[#$-:#IQ--! :T6]=KM[<(MM:;5D M$*0&J4%JD)K(4GME6I@4M$G2A+[2.URZPTLQ;%)>BF&3\E(,FY278MBDO!3# M)N6EG4JL:JZ@VCDME .>2O5>J5*I%#\)E>3%I]-RGYO77-MMR6*\'^_'^_?A M_8+M"!4UA;9,G^7$ONUJ:V^3E0"2:?%@&S&7MS3BF/96E[>ZF;POP$84**X( M$!5$<3UB&-!;Z"WT5BZ]-8EJ>-!;Z"WT5BZ]58FJ;K4%X. MY49JKP'*@')':J\!RH!R5VJO [P??KWPH&3[X1UB>5:+T53YM\/OTP()6*";+& 136LSBP$L !8 "[0=32&& MX;5=_!M, "8 $[1M#^@J,?3M'FD'&@ -B#%8H($UBN59>IM)DO+3@&!96*)& M/)_L<'S58HJ_LLMW&)RT62$HKFV+]MGKN] MLK@$09:82\O@ ?# VWE@NXGEX 'P@"BC!1Y8AP<,\ !X #RP[SR@PR\ #X ' MP /;38[8.QY WN<;\SYW%A+%?OF.[9=G_[:9WRFDGNWY/9A58JFHKP4P=P+,%M$<'6 &F#L 9L,AMFL#S&LXOQ\*OQ]3]F\8 MW7WZR'Y,&CG3V8 F!/J9\[?4H4_OU=%%I]:GMA M7Z6N85X[KN]HMAYZNN':?M^EQO]JZKN9FY8^<#)^:1YQ5_(HHS'S*>_H\7T4 M%H,C3648'-12M*KFS;O-[^1TY,?W_D/^]/UURRR3M6S=%TZO6,@W\P?]*5)>@=4C)C7]&2CY6;UQE-## MNA.:7K;\U,^+F'^@_$'#R%=.V2U^4#P]3G<)JGCM^.CZX;ER[+ASYH+.I>.L M2.B#\IT]E$K?G5%&\_RW7VSS.)B,VH#Z<3'H!>E0^M[ICGUH>OJAJ9ON!IV9 M3SAO^TY453U+[FA>I-ER;15QD*-L9?R*V'Q3LPY=W3O4;%==B-%ZAJVG)LUZ M;99=9<)<]YD+[E.WT191)N\/_31\8/\,BF'\Z?\ 4$L! A0#% @ 0X-9 M4!'+$=<=%0 EY( !$ ( ! &-S;'0M,C R,# R,C4N M:'1M4$L! A0#% @ 0X-94 R_ALBA @ &0H !$ ( ! M3!4 &-S;'0M,C R,# R,C4N>'-D4$L! A0#% @ 0X-94#(H^42$ 0 MU ( !4 ( !'!@ &-S;'0M,C R,# R,C5?8V%L+GAM;%!+ M 0(4 Q0 ( $.#65 V'_Z)( ( )@& 5 " =,9 !C M&@Y.3$M<')E